Robyn Karnauskas Analyst PerformanceAnalyst at Truist FinancialRobyn Karnauskas is a stock analyst at Truist Financial in the medical sector, covering 21 publicly traded companies. Over the past year, Robyn Karnauskas has issued 5 stock ratings, including buy and hold recommendations. While full access to Robyn Karnauskas' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robyn Karnauskas' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings87 Last 11 YearsBuy Recommendations89.16% 74 Buy RatingsCompanies Covered21 Unique Companies Ratings Distribution83RatingsDistribution of strong buy, buy, hold, and sell ratings by Robyn Karnauskas.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.2%74 ratings Hold9.6%8 ratings Sell1.2%1 ratingsOut of 83 total stock ratings issued by Robyn Karnauskas at Truist Financial, the majority (89.2%) have been Buy recommendations, followed by 9.6% Hold and 1.2% Sell.Best & Worst CallsBest Call000.0%IMVTDec 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DCPHApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ76.2% of companies on NASDAQ16 companiesNYSE23.8% of companies on NYSE5 companiesRobyn Karnauskas, an analyst at Truist Financial, currently covers 21 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical21 companies100.0%Robyn Karnauskas of Truist Financial specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies61.9%LARGE CAP PHARMA4 companies19.0%MED - DRUGS2 companies9.5%PHARMACEUTICAL PREPARATIONS2 companies9.5% Robyn Karnauskas' Ratings History at Truist Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLLYEli Lilly and Company2/23/2026Reiterated Rating$1,042.52Buy$0.0000.00% ROILLYEli Lilly and Company2/5/2026Set Price Target$1,034.59$1,281.00$0.0000.00% ROILLYEli Lilly and Company11/19/2025Boost Price Target$1,042.06$1,182.00Buy$0.0000.00% ROITRMLTourmaline Bio9/10/2025Downgrade$47.64$48.00Hold$0.0000.00% ROIABCLAbCellera Biologics5/16/2025Lower Price Target$2.04$10.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
